PR Newswire Clinical TrialsOriginal article
Galmed Announces First Time Results in Prostate Oncology Studies: Aramchol Demonstrates 3-4 Fold Increase in Cell Death Compared to Enzalutamide (XTANDI®) Alone in Prostate Cancer Models
Data ReadoutpositiveAramcholXtandiPositive
AI Analysis
Summary
Galmed announced preclinical results showing Aramchol achieved 3-4 fold greater cell death compared to enzalutamide alone in prostate cancer models. This represents the company's first disclosed data in prostate oncology studies.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
Aramchol demonstrated 3-4 fold increase in cell death compared to enzalutamide alone in prostate cancer models
Importance:5/10
Sentiment:
0.70
prostate canceroncologypreclinical datacell deathcombination therapy
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on August 17, 2026 1:15 PM